Cargando…
Trial by CCN2: a standardized test for fibroproliferative disease?
A major issue concerning clinical trials is the availability of standardized assays to evaluate drug efficacy. Ideally, such assays should test the effect of a putative drug on the expression of a biomarker in biological fluids. In a recent study by Kuiper et al. (PLOS One, 3(7): e2675). The relativ...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Springer Netherlands
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2686749/ https://www.ncbi.nlm.nih.gov/pubmed/19266315 http://dx.doi.org/10.1007/s12079-009-0041-y |